Dianthus Therapeutics' High Stakes Gamble on Autoimmune Diseases Dianthus Therapeutics has been making waves in the biotech industry with its aggressive approach to tackling autoimmune diseases.
The company's recent second quarter 2026 results and pipeline updates have left many observers wondering if this is a recipe for success or a recipe for disaster.
One of the most striking aspects of Dianthus' strategy is its willingness to spread itself thin across multiple programs at once.